ADARB2 and neoplasm: In this study, we identified a signature based on LINC00491, LINC00483, ADARB2-AS1, and C8orf49 to discriminate patients with endometrial cancer that are at increased risk for poor outcome in combination with the information related to TNM stage and type of neoplasm.